Aliases & Classifications for Acute Leukemia

About this section

Aliases & Descriptions for Acute Leukemia:

Name: Acute Leukemia 30 8 10 44 61
Stem Cell Leukemia 8 10
Acute Undifferentiated Leukemia 61
 
Undifferentiated Leukemia 61
Stem Cell Leukaemia 8


Classifications:



External Ids:

Disease Ontology8 DOID:12603
NCIt39 C9300, C9298
ICD9CM27 208.0

Summaries for Acute Leukemia

About this section
Disease Ontology:8 A leukemia that occurs when a hematopoietic stem cell undergoes malignant transformation into a primitive, undifferentiated cell with abnormal longevity. these lymphocytes (acute lymphocytic leukemia [all]) or myeloid cells (acute myelocytic leukemia [aml]) proliferate abnormally, replacing normal marrow tissue and hematopoietic cells and inducing anemia, thrombocytopenia, and granulocytopenia.

MalaCards based summary: Acute Leukemia, also known as stem cell leukemia, is related to myelodysplastic syndrome and myeloid leukemia. An important gene associated with Acute Leukemia is MKL1 (megakaryoblastic leukemia (translocation) 1), and among its related pathways are Hematopoietic cell lineage and Transcriptional misregulation in cancer. The compounds p00001 and etoposide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related mouse phenotypes are reproductive system and renal/urinary system.

Wikipedia:64 Acute leukemia or acute leukaemia is a family of serious medical conditions relating to an original... more...

Related Diseases for Acute Leukemia

About this section

Diseases in the Leukemia family:

acute leukemia Chronic Leukemia
Subacute Leukemia

Diseases related to Acute Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 190)
idRelated DiseaseScoreTop Affiliating Genes
1myelodysplastic syndrome31.3HOXA9, KMT2A, DNTT
2myeloid leukemia31.1DNTT, IL3RA, KMT2A, HOXA9
3megakaryocytic leukemia30.6KMT2A, MKL1
4myeloid sarcoma30.6DNTT, KMT2A
5acute myelomonocytic leukemia30.6KMT2A, DNTT
6lymphoblastic lymphoma30.4KMT2A, DNTT, TAL1, CD7
7chronic lymphocytic leukemia30.3KMT2A, IL3RA, DNTT
8leukemia30.1HOXA9, HOXA7, MKL1, ID4, KMT2A, TCF3
9leukemia, acute lymphoblastic28.9HOXA9, TRD, CD7, ID4, KMT2A, TCF3
10hematopoietic stem cell transplantation10.7
11lymphoblastic leukemia10.5
12wilms tumor10.4
13aspergillosis10.4
14multiple myeloma10.4
15acute biphenotypic leukemia10.4
16myeloma10.4
17granulocytopenia10.4
18candidiasis10.3
19refractory anemia10.3
20breast cancer10.3
21hepatitis10.3
22neutropenia10.3
23invasive aspergillosis10.3
24down syndrome10.3
25disseminated intravascular coagulation10.3
26sarcoma10.3
27blindness10.3
28chronic myelomonocytic leukemia10.2
29systemic mastocytosis10.2
30rhabdomyosarcoma10.2
31sideroblastic anemia10.2
32tetraploidy10.2
33endotheliitis10.2
34bilineal acute leukemia10.2
35leukemia, acute myeloid10.2
36bloom syndrome10.2
37li-fraumeni syndrome10.2
38neuroblastoma10.2
39hodgkin lymphoma10.2
40thrombocytopenia10.2
41appendicitis10.2
42oral candidiasis10.2
43pernicious anemia10.2
44histiocytosis10.2
45essential thrombocythemia10.2
46leukopenia10.2
47acute lymphoblastic leukemia, childhood10.2TRD, DNTT, MTHFR, KMT2A
48precursor b-cell acute lymphoblastic leukemia10.1DNTT, KMT2A
49priapism10.1
50myeloid neoplasm associated with fgfr1 rearrangement10.1

Graphical network of the top 20 diseases related to Acute Leukemia:



Diseases related to acute leukemia

Symptoms for Acute Leukemia

About this section

Drugs & Therapeutics for Acute Leukemia

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
1
Busulfex13 38 BUSULFAN Orphan Medical Approved February 1999
FDA Label: Busulfex
Malady that Drug Treats: leukemia
Indications and Usage:13 BUSULFEX is an alkylating drug indicated for:; Use in combination with cyclophosphamide as a conditioning regimen; prior to allogeneic hematopoietic progenitor cell transplantation for; chronic myelogenous leukemia (CML) (1)
DrugBank Targets:11 DNA
Mechanism of Action:13 
Target: DNA
Action: alkylyzer
FDA: Busulfan is a bifunctional alkylating agent in which two labile methanesulfonate groups are attached to opposite ends of a; four-carbon alkyl chain. In aqueous media, busulfan hydrolyzes to release the methanesulfonate groups. This produces; reactive carbonium ions that can alkylate DNA. DNA damage is thought to be responsible for much of the cytotoxicity of; busulfan.
2
Clolar13 38 CLOFARABINE Genzyme Approved December, 2004
FDA Label: Clolar
Malady that Drug Treats: Lymphoblastic Leukemia
Indications and Usage:13 Clolar (clofarabine) injection is a purine nucleoside metabolic inhibitor; indicated for the treatment of pediatric patients 1 to 21 years old with relapsed; or refractory acute lymphoblastic leukemia after at least two prior regimens.; This indication is based upon response rate. There are no trials verifying an; improvement in disease-related symptoms or increased survival with Clolar.; (1)
DrugBank Targets:11 1. DNA polymerase alpha catalytic subunit; 2. Ribonucleoside-diphosphate reductase large subunit; 3. DNA
Mechanism of Action:13 
Target: ribonucleotide reductase
Action: inhibitor
FDA: Clofarabine is sequentially metabolized intracellularly to the 5 -monophosphate metabolite by; deoxycytidine kinase and mono- and di-phospho-kinases to the active 5 -triphosphate metabolite.; Clofarabine has affinity for the activating phosphorylating enzyme, deoxycytidine kinase, equal; to or greater than that of the natural substrate, deoxycytidine. Clofarabine inhibits DNA synthesis; by decreasing cellular deoxynucleotide triphosphate pools through an inhibitory action on; ribonucleotide reductase, and by terminating DNA chain elongation and inhibiting repair through; incorporation into the DNA chain by competitive inhibition of DNA polymerases. The affinity of; clofarabine triphosphate for these enzymes is similar to or greater than that of deoxyadenosine; triphosphate. In preclinical models, clofarabine has demonstrated the ability to inhibit DNA; repair by incorporation into the DNA chain during the repair process. Clofarabine 5 -; triphosphate also disrupts the integrity of mitochondrial membrane, leading to the release of the; pro-apoptotic mitochondrial proteins, cytochrome C and apoptosis-inducing factor, leading to; programmed cell death.; Clofarabine is cytotoxic to rapidly proliferating and quiescent cancer cell types in vitro.
3
Marqibo13 38 VINCRISTINE SULFATE Talon Therapeutics Approved August 2012
FDA Label: Marqibo
Malady that Drug Treats: Ph- acute lymphoblastic leukemia
Indications and Usage:13 Marqibo is a vinca alkaloid indicated for the treatment of adult patients with; Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL); in second or greater relapse or whose disease has progressed following two or; more anti-leukemia therapies. This indication is based on overall response; rate. Clinical benefit such as improvement in overall survival has not been; verified (1.1).
DrugBank Targets:11 1. Tubulin beta chain; 2. Tubulin alpha-4A chain
Mechanism of Action:13 
Target: tubulin
Action: alters polymerization equilibrium
FDA: Marqibo is a sphingomyelin/cholesterol liposome-encapsulated formulation of vincristine sulfate.; Non-liposomal vincristine sulfate binds to tubulin, altering the tubulin polymerization equilibrium, resulting in; altered microtubule structure and function. Non-liposomal vincristine sulfate stabilizes the spindle apparatus,; preventing chromosome segregation, triggering metaphase arrest and inhibition of mitosis.

Drug clinical trials:

Search ClinicalTrials for Acute Leukemia

Search NIH Clinical Center for Acute Leukemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Acute Leukemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Acute Leukemia:
Promostem

Genetic Tests for Acute Leukemia

About this section

Anatomical Context for Acute Leukemia

About this section

MalaCards organs/tissues related to Acute Leukemia:

31
Myeloid, Bone, Bone marrow, T cells, Lung, Breast, Nk cells, B cells, Endothelial, Neutrophil, Brain, Testes, Monocytes, Liver, Thyroid, Lymph node, Skeletal muscle, Skin

Animal Models for Acute Leukemia or affiliated genes

About this section

MGI Mouse Phenotypes related to Acute Leukemia:

35
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053899.1ZNF384, MTHFR, FOXO3, TCF3, KMT2A, HOXA9
2MP:00053679.1KMT2A, TCF3, FOXO3, TAL1, TRD
3MP:00107718.8HOXA9, MKL1, KMT2A, TCF3, FOXO3, MTHFR
4MP:00053908.6HOXA9, HOXA7, ID4, KMT2A, MTHFR, ZNF384
5MP:00053788.4HOXA9, MKL1, ID4, KMT2A, TCF3, MTHFR
6MP:00053977.6TRD, HOXA9, HOXA7, KMT2A, TCF3, LYL1
7MP:00053877.6TCF3, KMT2A, HOXA7, HOXA9, LYL1, FOXO3

Publications for Acute Leukemia

About this section

Articles related to Acute Leukemia:

(show top 50)    (show all 1438)
idTitleAuthorsYear
1
Pro-Survival Role Of Protein Kinase C Epsilon in Philadelphia Chromosome Positive Acute Leukemia. (25904380)
2015
2
Biological activities of RUNX1 mutants predict secondary acute leukemia transformation from chronic myelomonocytic leukemia and myelodysplastic syndromes. (25840971)
2015
3
MicroRNA profiling reveals aberrant microRNA expression in adult ETP-ALL and functional studies implicate a role for miR-222 in acute leukemia. (23522449)
2013
4
Expression of homeobox gene HOXA9 in childhood acute leukemia, and its clinical significance]. (23607948)
2013
5
Biphenotypic Acute Leukemia with t(15;17) Lacking Promyelocytic-retinoid Acid Receptor I+ Rearrangement. (24416501)
2013
6
Pre-clinical evaluation of tyrosine kinase inhibitors for treatment of acute leukemia. (24084362)
2013
7
The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT. (22773125)
2013
8
CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia. (22261446)
2012
9
Evaluation of multidrug resistance in 46 newly diagnosed patients with acute leukemia. (22664042)
2012
10
124I-anti-CD52 dosimetry before radioimmunotherapy as part of conditioning for stem cell transplantation in acute leukemia. (22391715)
2012
11
Measurements of treatment response in childhood acute leukemia. (23320002)
2012
12
Association of insulin like growth factor-1 (IGF-1) and thyroid hormones in patients of acute leukemia. (22582495)
2012
13
Abnormal expression of P2X family receptors in Chinese pediatric acute leukemias. (19919827)
2010
14
Genetic polymorphisms of the lymphotoxin alpha gene are associated with increased risk for lethal infections during induction therapy for childhood acute leukemia: a case-control study. (19353239)
2009
15
Association of CYP2B6 G15631T polymorphism with acute leukemia susceptibility. (19144407)
2009
16
Analysis of NOTCH1 extracellular juxtamembrane expansion mutations in acute leukemias and multiple myelomas. (19239437)
2009
17
Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. (17252021)
2007
18
ANKHD1, ankyrin repeat and KH domain containing 1, is overexpressed in acute leukemias and is associated with SHP2 in K562 cells. (16956752)
2006
19
IgH and TCRgamma gene rearrangements, cyclin A1 and HOXA9 gene expression in biphenotypic acute leukemias. (16102826)
2006
20
Prognostic significance of multidrug resistance gene 1 (MDR1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) mRNA expression in acute leukemia. (16614510)
2006
21
Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. (15388581)
2005
22
Acremonium pyomyositis in a pediatric patient with acute leukemia. (15593233)
2005
23
Study on clinical and biological characteristics of childhood acute leukemia with MLL gene rearrangements]. (16383239)
2005
24
Interleukin-3 receptor in acute leukemia. (14671644)
2004
25
Survivin expression in acute leukemias and myelodysplastic syndromes. (15512811)
2004
26
Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. (14726393)
2004
27
Study on efficacy of treatment of acute leukemia by shengfu injection in combination with chemotherapy and the effect on cellular immunity, serum interleukin-6 and tumor necrosis factor-alpha levels]. (12764905)
2003
28
Expression of transporter associated with antigen processing (TAP) in childhood acute leukemia and its clinical significance]. (14558951)
2003
29
Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels. (12148910)
2002
30
Quantitative analysis of a MDR1 transcript for prediction of drug resistance in acute leukemia. (12028995)
2002
31
Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. (11234890)
2001
32
Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. (11090076)
2000
33
Temporary remission of an alveolar rhabdomyosarcoma diagnosed and treated as acute leukemia. (10674913)
2000
34
BP1, a new homeobox gene, is frequently expressed in acute leukemias. (11069021)
2000
35
E-cadherin expression is silenced by 5' CpG island methylation in acute leukemia. (11106238)
2000
36
Thiorphan, an inhibitor of neutral endopeptidase/enkephalinase (CD10/CALLA) enhances cell proliferation in bone marrow cultures of patients with acute leukemia in remission. (10841318)
2000
37
Alterations in subnuclear trafficking of nuclear regulatory factors in acute leukemia. (11389537)
2000
38
wt1 gene expression in childhood acute leukemias. (11014901)
2000
39
Megakaryocyte growth and development factor (MGDF)-induced acute leukemia cell proliferation and clonal growth is associated with functional c-mpl. (9096694)
1997
40
Terminal transferase expression in the differential diagnosis of acute leukemias. Eastern Cooperative Oncology Group. (8819075)
1996
41
Increased expression of the Wilms tumor gene (WT1) at relapse in acute leukemia. (8943879)
1996
42
Transcobalamin II levels in blood plasma of children with acute leukemia]. (8754152)
1996
43
Usefulness of immunocytochemistry for phenotypical analysis of acute leukemia; improved fixation procedure and comparative study with flow cytometry. (7719239)
1995
44
Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. (7596170)
1995
45
Characterization of translocation t(1;14)(p32;q11) in a T and in a B acute leukemia. (8412312)
1993
46
Immunological detection of myeloperoxidase in poorly differentiated acute leukemia. (8386105)
1993
47
Biological parameters of the efficiency of retinoic acid in acute leukemia]. (1822394)
1991
48
Genuine CD7 expression in acute leukemia and lymphoblastic lymphoma. (1701841)
1990
49
Testicular disease in Singapore children with acute leukemia. (6595957)
1984
50
Serum migration-inhibitory activity in patients with acute leukemia and early leukemic lymphosarcoma. (387315)
1979

Variations for Acute Leukemia

About this section

Expression for genes affiliated with Acute Leukemia

About this section
Search GEO for disease gene expression data for Acute Leukemia.

Pathways for genes affiliated with Acute Leukemia

About this section

Pathways related to Acute Leukemia according to GeneCards Suite gene sharing:

idSuper pathways (with members indented)ScoreTop Affiliating Genes
19.5CD7, DNTT, IL3RA
29.2TAF15, LYL1, TCF3, KMT2A, HOXA9

Compounds for genes affiliated with Acute Leukemia

About this section

Compounds related to Acute Leukemia according to GeneCards Suite gene sharing:

idCompoundScoreTop Affiliating Genes
1p000014410.1MTHFR, KMT2A
2etoposide44 50 60 1112.4TAL1, DNTT, FOXO3, KMT2A
3retinoic acid44 2410.1KMT2A, MTHFR, DNTT, MXD1, TAL1

GO Terms for genes affiliated with Acute Leukemia

About this section

Cellular components related to Acute Leukemia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1nucleusGO:00056346.8TAL1, HOXA7, MKL1, ID4, KMT2A, TCF3

Biological processes related to Acute Leukemia according to GeneCards Suite gene sharing:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1embryonic hemopoiesisGO:00351629.9TAL1, KMT2A
2definitive hemopoiesisGO:00602169.9LYL1, TAL1
3positive regulation of erythrocyte differentiationGO:00456489.8TAL1, FOXO3
4negative regulation of transcription from RNA polymerase II promoterGO:00001229.3TAL1, FOXO3, ID4, HOXA7
5positive regulation of transcription, DNA-templatedGO:00458939.1KMT2A, TCF3, LYL1, FOXO3, TAF15, TAL1
6positive regulation of transcription from RNA polymerase II promoterGO:00459448.7TAL1, HOXA7, MKL1, ID4, KMT2A, TCF3
7transcription, DNA-templatedGO:00063518.3HOXA9, HOXA7, MKL1, TCF3, PRAME, LYL1

Molecular functions related to Acute Leukemia according to GeneCards Suite gene sharing:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1E-box bindingGO:007088810.0TAL1, TCF3
2transcription regulatory region DNA bindingGO:00442129.9KMT2A, TCF3, TAL1
3protein dimerization activityGO:00469839.5MXD1, LYL1, ID4
4RNA polymerase II transcription factor bindingGO:00010859.5ID4, TAL1
5sequence-specific DNA bindingGO:00435659.4HOXA9, HOXA7, TCF3, FOXO3, ZNF384
6DNA bindingGO:00036779.0TCF3, LYL1, FOXO3, DNTT, MXD1, TAF15
7sequence-specific DNA binding transcription factor activityGO:00037008.8TAL1, HOXA9, HOXA7, MKL1, KMT2A, TCF3
8protein bindingGO:00055157.8MKL1, ID4, KMT2A, TCF3, PRAME, LYL1

Sources for Acute Leukemia

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet